AbbVie Inc. $ABBV Shares Sold by NFJ Investment Group LLC

NFJ Investment Group LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 107,711 shares of the company’s stock after selling 18,911 shares during the period. NFJ Investment Group LLC’s holdings in AbbVie were worth $24,611,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Financial Gravity Asset Management Inc. increased its position in shares of AbbVie by 26.4% in the fourth quarter. Financial Gravity Asset Management Inc. now owns 316 shares of the company’s stock worth $72,000 after acquiring an additional 66 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of AbbVie by 40.4% in the fourth quarter. Focus Partners Wealth now owns 912,360 shares of the company’s stock valued at $208,447,000 after purchasing an additional 262,552 shares during the period. Glen Eagle Advisors LLC boosted its stake in shares of AbbVie by 11.5% in the fourth quarter. Glen Eagle Advisors LLC now owns 21,115 shares of the company’s stock valued at $4,825,000 after purchasing an additional 2,173 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of AbbVie by 253.0% in the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 246,869 shares of the company’s stock valued at $56,407,000 after purchasing an additional 176,935 shares during the period. Finally, Horizon Investment Services LLC boosted its stake in shares of AbbVie by 17.2% in the fourth quarter. Horizon Investment Services LLC now owns 1,573 shares of the company’s stock valued at $359,000 after purchasing an additional 231 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Performance

AbbVie stock opened at $227.54 on Friday. The firm’s 50-day moving average is $211.05 and its 200-day moving average is $219.07. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $244.81. The company has a market cap of $402.02 billion, a P/E ratio of 112.09, a PEG ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the firm posted $2.46 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, sell-side analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ABBV. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Morgan Stanley increased their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.